Physician profile
Kylie Abe
NPI 1609238823
$16,161.06
in general payments reported to CMS, 2019-2025
17 companies · $1,544 in 2025
The $1,544 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12K · 2022: $1,626 · 2023: $249 · 2024: $500 · 2025: $1,544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,600 · Travel and Lodging: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,599.59 |
| Travel and Lodging | $692.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $12,471.56 | 2021-2025 | Percept PC Brainsense |
| Boston Scientific Corporation | $2,508.11 | 2022-2025 | Vercise, General - Dbs |
| Abbvie INC. | $407.61 | 2023-2025 | Ubrelvy, Qulipta |
| Abbott Laboratories | $202.06 | 2022-2024 | Infinity |
| Teva Pharmaceuticals USA, INC. | $127.68 | 2023-2025 | Austedo Xr, Austedo Xr |
| Celgene Corporation | $112.70 | 2022-2024 | Zeposia |
| Emd Serono, INC. | $69.64 | 2022-2025 | Mavenclad |
| Merz Pharmaceuticals, LLC | $48.03 | 2024 | Xeomin |
| Genentech USA, INC. | $36.77 | 2024-2025 | Ocrevus Zunovo |
| Argenx US, INC. | $33.62 | 2025 | Vyvgart |
| Genzyme Corporation | $25.25 | 2022 | |
| Acadia Pharmaceuticals INC | $24.36 | 2022 | |
| Pfizer INC. | $22.83 | 2025 | |
| Acorda Therapeutics, INC | $21.31 | 2024 | Ampyra, Inbrija |
| Kyowa Kirin, INC. | $17.81 | 2023 | Nourianz |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $16.32 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $15.40 | 2023 | Dysport |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kylie Abe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.